Clinical Trial Search

Primary: Number of Participants With Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) — 22 Participants — p=<0.001

Primary: Number of Participants With Plasma 25(OH)D Concentration >30ng/mL at Baseline — 2; 2; 1 participants

Primary: Response Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria — 66.7; 83.3; 68.8; 39.4 percentage of patients

Primary: Median Overall Survival (OS) — 14.09 months

Primary: Number of Participants With Peanut Allergy (PA) at 72 Months of Age - by Skin Prick Test Stratum — 34; 7; 18; 6 Participants — p=<0.001

Primary: Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant Medication — 2; 0; 2; 0 Participants

Primary: Number of Subjects With Solicited Local Symptoms — 20; 6; 1; 1 Subjects

Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants

Primary: Overall Response Rate — 0.0 proportion of participants

Primary: Proportion of Subjects Who Require Resumption of ART Between the Interruption of ART at Week 28 and End of Study at Week 52. — 88; 40; 88; 38 participants

Primary: Minimum Plasma Concentration (Cmin) of Simeprevir (SMV) — 2411; 6701 nanogram per Milliliters (ng/mL)

Primary: Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants…

Primary: Selection of One of Two Treatment Regimens (Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel) for Further Study in a Phase III Trial, Based on Median…

Primary: Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF)…

Primary: 6-month Progression-free Survival — 0.263; 0.171 proportion of participants